Related Experiment Video
Updated: Sep 11, 2025
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Blinatumomab Administration in Pediatric B-Lineage ALL: Expert Recommendations From the Children's Oncology Group
Holly R Kubaney1, Kathleen E Montgomery2, Lauren Guidry3
1Holly R. Kubaney.
Insights
Blinatumomab is now standard for pediatric B-lineage acute lymphoblastic leukemia (B-ALL), but its administration presents challenges. Expert recommendations guide safe and effective blinatumomab use in children with B-ALL.
Area of Science:
- Pediatric Hematology Oncology
- Pharmacology and Therapeutics
Background:
- Blinatumomab plus chemotherapy is the standard of care for pediatric B-lineage acute lymphoblastic leukemia (B-ALL).
- Rapid increase in blinatumomab use presents unique administration challenges and practice variations.
Purpose of the Study:
- To provide expert recommendations for blinatumomab administration in pediatric B-ALL patients.
- To address challenges and standardize practices for blinatumomab therapy in children.
Main Methods:
- Multidisciplinary expert panel (nurses, physicians, pharmacists) convened.
- Current evidence and Children's Oncology Group institutional experiences were collated.
- Key considerations for planning, initiation, management, and adverse event monitoring were identified.
Main Results:
- Patient, family, and clinician engagement is crucial for care transitions and complication minimization.
- Continuous institutional monitoring of blinatumomab administration trends is recommended.
- Emerging data can inform future optimal care practices for blinatumomab therapy.
Conclusions:
- Standardized recommendations are needed to optimize blinatumomab administration in pediatric B-ALL.
- Multidisciplinary collaboration and ongoing monitoring are essential for safe and effective treatment.
- Evidence-based guidelines will improve patient outcomes and minimize treatment-related complications.
Background:
The addition of blinatumomab to chemotherapy is the new standard of care for most pediatric patients with B-lineage acute lymphoblastic leukemia (B-ALL), and its use has increased rapidly. Administering blinatumomab to pediatric patients is associated with a spectrum of unique challenges, resulting in variable practices across institutions.
Objectives:
This article presents expert recommendations for blinatumomab administration in patients with pediatric B-ALL.
Methods:
Pediatric oncology nurses, physicians, and pharmacists collated current evidence and Children's Oncology Group institutional experiences to identify considerations for planning for blinatumomab administration, initiating and managing infusions, and monitoring for adverse events.
Findings:
Engaging patients, families, and clinicians promotes care transitions between inpatient and outpatient settings and minimizes complications. Ongoing institutional commitment to monitor and capture emerging trends in blinatumomab administration can inform future optimal care practices.
More Related Videos
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
06:18Author Spotlight: Advancements in CAR-T Cell Manufacturing and Gene Therapy Production
Published on: August 18, 2023
